BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 19381817)

  • 1. Brain and optic chiasmal herniations into sella after cabergoline therapy of giant prolactinoma.
    Dhanwal DK; Sharma AK
    Pituitary; 2011 Dec; 14(4):384-7. PubMed ID: 19381817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain and optic chiasmal herniation following cabergoline treatment for a giant prolactinoma: wait or intervene?
    Papanastasiou L; Fountoulakis S; Pappa T; Liberopoulos K; Malliopoulos D; Markou A; Piaditis G
    Hormones (Athens); 2014; 13(2):290-5. PubMed ID: 24776630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma.
    Raverot G; Jacob M; Jouanneau E; Delemer B; Vighetto A; Pugeat M; Borson-Chazot F
    Clin Endocrinol (Oxf); 2009 Apr; 70(4):588-92. PubMed ID: 18673461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chiasmal herniation as a complication of bromocriptine therapy.
    Taxel P; Waitzman DM; Harrington JF; Fagan RH; Rothfield NF; Chen HH; Malchoff CD
    J Neuroophthalmol; 1996 Dec; 16(4):252-7. PubMed ID: 8956160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transnasal Transsphenoidal Elevation of Optic Chiasm in Secondary Empty Sella Syndrome Following Prolactinoma Treatment.
    Cobb MIH; Crowson M; Mintz-Cole R; Husain AM; Berger M; Jang D; Codd P
    World Neurosurg; 2018 Apr; 112():250-253. PubMed ID: 29421446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain & chiasmal herniations into sella after medical treatment of prolactinoma.
    Bangash MH; Clarke DB; Holness RO
    Can J Neurol Sci; 2006 May; 33(2):240-2. PubMed ID: 16736739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endoscopic transsphenoidal treatment of a prolactinoma patient with brain and optic chiasmal herniations.
    Zhang N; Guo L; Ge J; Qiu Y
    J Craniofac Surg; 2014 May; 25(3):e271-2. PubMed ID: 24820730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Untethering of herniated left optic nerve after dopamine agonist treatment for giant prolactinoma.
    Gkekas N; Primikiris P; Georgakoulias N
    Acta Neurochir (Wien); 2013 Mar; 155(3):495-6. PubMed ID: 23314935
    [No Abstract]   [Full Text] [Related]  

  • 9. Pons herniation into skull base after cabergoline therapy of giant prolactinoma.
    Moles Herbera J; Rivero Celada D; Montejo Gañan I; Fustero de Miguel D; Fuentes Uliaque C; Vela Marín AC
    Pituitary; 2015 Feb; 18(1):68-71. PubMed ID: 24522845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour shrinkage and chiasmal herniation after successful cabergoline treatment for a macroprolactinoma.
    Marcos L; De Luis DA; Botella I; Hurtado A
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):126-7. PubMed ID: 11167937
    [No Abstract]   [Full Text] [Related]  

  • 11. Pituitary apoplexy associated with cabergoline therapy.
    Chng E; Dalan R
    J Clin Neurosci; 2013 Dec; 20(12):1637-43. PubMed ID: 24113159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What causes a prolactinoma to be aggressive or to become a pituitary carcinoma?
    Phillips J; East HE; French SE; Melcescu E; Hamilton RD; Nicholas WC; Fratkin JF; Parent AD; Luzardo G; Koch CA
    Hormones (Athens); 2012; 11(4):477-82. PubMed ID: 23422771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid improvement in visual loss with cabergoline treatment in a giant prolactinoma case: 5 years survey.
    Tasan E; Hanimoglu H; Turgut S; Ilhan MM; Evran S; Kaynar MY
    Neuro Endocrinol Lett; 2015; 36(1):28-30. PubMed ID: 25789596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Status epilepticus induced by treatment with dopamine agonist therapy for giant prolactinoma: a case report.
    Koguchi M; Nakahara Y; Ebashi R; Ogata A; Shimokawa S; Masuoka J; Abe T
    J Med Case Rep; 2019 Jan; 13(1):18. PubMed ID: 30660191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optic chiasmal herniation--an under recognized complication of dopamine agonist therapy for macroprolactinoma.
    Jones SE; James RA; Hall K; Kendall-Taylor P
    Clin Endocrinol (Oxf); 2000 Oct; 53(4):529-34. PubMed ID: 11012580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.
    Wu ZB; Su ZP; Wu JS; Zheng WM; Zhuge QC; Zhong M
    Pituitary; 2008; 11(1):63-70. PubMed ID: 17917811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cabergoline-induced tension pneumocephalus in a patient with giant invasive prolactinoma. Case report].
    Castro-Castro J; Torre-Eiriz JA; Pinzón-Millán A; Pastor-Zapata A
    Neurocirugia (Astur); 2011 Dec; 22(6):558-61; discussion 561. PubMed ID: 22167286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Giant pubertal prolactinoma: Complete resolution following short term carbegoline treatment.
    Oguz A; Tuzun D; Sahin M; Gul K
    Niger J Clin Pract; 2016; 19(5):685-7. PubMed ID: 27538562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine.
    Delgrange E; Maiter D; Donckier J
    Eur J Endocrinol; 1996 Apr; 134(4):454-6. PubMed ID: 8640297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.